
Superantigen T cell: APC priming assay
FcγR
CD226
PVR
CD96
PVR
TIGIT
APC
T cell
CYTOKINES & ACTIVATION MARKERS
MHC
TCR
SEA

FIG. 1A


Donor 1
IL-2 [pg/mL]
<0.001
<0.001
<0.001
<0.001
<0.001
0.002
Isotype Control
AGEN1777
Balstilimab
AGEN1777 + anti-PD-1
Donor 2
IL-2 [pg/mL]
<0.001
<0.001
<0.001
<0.001
0.95
0.004
Isotype Control
AGEN1777
Balstilimab
AGEN1777 + anti-PD-1

FIG. 1B


Donor 1
IL2 [pg/mL]
500
400
300
200
100
0
<0.001
<0.001
0.67
<0.001
<0.001
0.63
<0.001
<0.001
0.10
Isotype Control
Tiragolumab
AGEN1777
Nivolumab
Tiragolumab + Nivolumab
AGEN1777 + Nivolumab
Atezolumab
Tiragolumab + Atezolumab
AGEN1777 + Atezolumab

FIG. 1C


Donor 2
IL2 [pg/mL]
400
300
200
100
0
0.27
0.008
0.010
0.04
<0.001
<0.001
0.14
<0.001
<0.001
Isotype Control
Tiragolumab
AGEN1777
Nivolumab
Tiragolumab + Nivolumab
AGEN1777 + Nivolumab
Atezolumab
Tiragolumab + Atezolumab
AGEN1777 + Atezolumab

FIG. 1D


CT26 Early Intervention Model
(Tumor volume: ~45mm3)
Tumor volume (mm3)
3000
2000
1000
0
0
20
40
60
Days post implantation
Isotype Control
anti-CD96 mAb
anti-TIGIT mAb
AGEN1777ms
AGEN1777ms +
anti-PD-1
*
*
****

FIG. 2A


Isotype Control
(Bispecific)
anti-TIGIT
(mAb)
anti-CD96
(mAb)
anti-PD-1
(mAb; RMP1-14)
CR: 0/10
CR:1/8
CR:0/8
AGEN1777ms
(Knob-in-hole)
CR:4/8
AGEN1777ms + anti-PD-1
(Knob-in-hole + mAb)
CR:5/8
Tumor volume (mm3)
Days post implantation
0
500
1000
1500
2000
0
20
40
60
Isotype Control
anti-PD-1

FIG. 2B


CT26 Late Intervention Model
(Tumor volume: ~100mm3)
Tumor volume (mm3)
3000
2000
1000
0
0
10
20
30
40
50
Days post implantation
*
*
****
Isotype Control
AGEN1777ms
AGEN1777ms + anti-PD-1

FIG.3A


Isotype Control
(Bispecific)
AGEN1777ms
(Bispecific)
CR:2/8
AGEN1777ms + anti-PD-1
(Bispecific + mAb)
CR:5/8
Tumor volume (mm3)
Days post implantation
0
500
1000
1500
2000
0
20
40
60

FIG.3B